Effect of a long-term oral l-arginine supplementation on glucose metabolism: A randomized, double-blind, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 14, Issue 10, 2012, Pages 893-900

  Monti, L D ^a   Setola, E ^a   Lucotti, P C G ^a   Marrocco Trischitta, M M ^a   Comola, M ^a   Galluccio, E ^a   Poggi, A ^a   Mammi S ^a   Catapano, A L ^b   Comi, G ^a   Chiesa, R ^a   Bosi, E ^a   Piatti, P M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Endothelium; Glucose metabolism; Insulin resistance; Insulin secretion; L arginine

Indexed keywords

ARGININE; GLUCOSE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL GLUCOSE TOLERANT; ORAL GLUCOSE TOLERANCE TEST; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84865965117     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01615.x     Document Type: Article

References (38)

1. McKnight JR, Satterfield MC, Jobgen WS et al. Beneficial effects of l-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids 2010; 39: 349-357.
2. Wu G, Bazer FW, Davis TA et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37: 153-168.
3. Clarkson P, Adams MR, Powe AJ et al. Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-1994.
4. Wascher TC, Graier WF, Dittrich P et al. Effects of low-dose l-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Invest 1997; 27: 690-695.
5. Boger RH. The pharmacodynamics of l-arginine. J Nutr 2007; 137: 1650S-1655S.
6. Kim F, Pham M, Maloney E et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1982-1988.
7. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
8. The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events, N Engl J Med 2010; 362: 1463-1479.
9. Piatti PM, Monti LD, Valsecchi G et al. Long-term oral l-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001; 24: 875-880.
10. Lucotti P, Setola E, Monti LD et al. Beneficial effects of a long-term oral l-arginine added to a hypocaloric diet and exercise training program in obese, insulin-resistant 2 diabetic patients. Am J Physiol Endocrinol Metab 2006; 291: E906-E912.
11. Lucotti P, Monti LD, Setola E et al. Oral l-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism 2009; 58: 1270-1276.
12. Mason CC, Hanson RL, Knowler WC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes 2007; 56: 2054-2061.
13. Mohan IK, Das UN. Effect of l-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med 1998; 25: 757-765.
14. Méndez JD, De Haro Hernández R. l-Arginine and polyamine administration protect b-cells against alloxan diabetogenic effect in Sprague-Dawley rats. Biomed Pharmacol 2005; 59: 283-289.
15. Vasilijević A, Buzadić B, Korać A et al. Beneficial effects of l-arginine-nitric oxide-producing pathway in rats treated with alloxan. J Physiol 2007; 584: 921-933.
16. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
17. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
18. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
19. DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-1115.
20. Cnop M, Vidal J, Hull RL et al. Progressive loss of β-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682.
21. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
22. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144.
23. Piatti P, Di Mario C, Monti LD et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-2081.
24. Tan B, Yin Y, Liu Z et al. Dietary l-arginine supplementation differentially regulates expression of lipid-metabolic genes in porcine adipose tissue and skeletal muscle. J Nutr Biochem 2011; 22: 441-445.
25. Doutreleau S, Rouyer O, Di Marco P et al. l-Arginine supplementation improves exercise capacity after a heart transplant. Am J Clin Nutr 2010; 91: 1261-1267.
26. Bai Y, Sun L, Yang T et al. Increase in fasting vascular endothelial function after short-term oral l-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2009; 89: 77-84.
27. Bednarz B, Jaxa-Chamiec T, Maciejewski P et al. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol 2005; 62: 421-427.
28. Yin WH, Chen JW, Tsai C et al. l-Arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr 2005; 24: 988-997.
29. Rector TS, Bank AJ, Mullen KA et al. Randomized, double-blind, placebo-controlled study of supplemental oral l-arginine in patients with heart failure. Circulation 1996; 93: 2135-2141.
30. Schulman SP, Becker LC, Kass DA et al. l-Arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.
31. Boger RH. Letter to the editor re: JAMA article on l-arginine therapy in acute myocardial infarction. Altern Med Rev 2006; 11: 91-92.
32. Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686
33. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783-1789.
34. Lindström J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
35. Jensen CC, Cnop M, Hull RL, the American Diabetes Association GENNID Study Group et al. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-2178.
36. Hanley AJ, Zinman B, Sheridan P, The Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) Investigators et al. Effect of rosiglitazone and ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010; 33: 608-613.
37. Mykkänen L, Haffner SM, Hales CN et al. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 1997; 46: 1990-1995.
38. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program. Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414.